NCT04670107View on ClinicalTrials.gov

The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

October 1, 2020

Study Completion Date

November 1, 2020

Conditions
NSCLCAngiogenesisImmunotherapy
Interventions
DRUG

Anlotinib in combination with Immune checkpoint inhibitors

Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)

Trial Locations (1)

Unknown

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT04670107 - The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy | Biotech Hunter | Biotech Hunter